Managed-Care Organizations In Clinical Trials RAY OF HOPE: Cancer-prevention specialist Jon Kerner says MCOs support Phase III trials in some cases. With the advent of managed-care organizations (MCOs) and their focus on cost competitiveness, academic scientists are concerned that clinical trials will suffer from decreased patient participation. MCOs, they say, have been refusing to pay for ancillary tests and procedures performed in the course of a trial that they would otherwise pay. Resear
Managed-Care Organizations In Clinical Trials
 RAY OF HOPE: Cancer-prevention specialist Jon Kerner says MCOs support Phase III trials in some cases. |
MCOs claim that clinical-trial expenses are not part of their responsibility to provide cost-effective care. But some people affiliated with MCOs point out that under the right circumstances, their organizations will participate in ...
Memory-enhancing neural networks may also drive involuntary musical loops in the brain.
View this Issue
In this webinar, Felix Lansing will discuss how AI-driven models improve recombinase development.
In this webinar, Brian Hie will discuss Evo2, a state-of-the-art genomic foundation model capable of generalist prediction and design tasks across DNA, RNA, and proteins.
In this webinar, learn how scientists use advanced human brain models to uncover treatment strategies for complex neurological conditions.
In the dynamic biotechnology and biopharmaceutical science fields, qPCR and dPCR multiplexing has emerged as a crucial technique for accelerated and consistent research workflows.
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model
Zymo Research, a global leader in sample preparation technologies and sustainable life science solutions, will partner with Harvard University to host the BioFestival on October 18, 2025.
Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases
This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.
